Cargando…
Vaccine Safety Surveillance Using Routinely Collected Healthcare Data—An Empirical Evaluation of Epidemiological Designs
Background: Routinely collected healthcare data such as administrative claims and electronic health records (EHR) can complement clinical trials and spontaneous reports to detect previously unknown risks of vaccines, but uncertainty remains about the behavior of alternative epidemiologic designs to...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299244/ https://www.ncbi.nlm.nih.gov/pubmed/35873596 http://dx.doi.org/10.3389/fphar.2022.893484 |
_version_ | 1784750922037985280 |
---|---|
author | Schuemie, Martijn J. Arshad, Faaizah Pratt, Nicole Nyberg, Fredrik Alshammari, Thamir M Hripcsak, George Ryan, Patrick Prieto-Alhambra, Daniel Lai, Lana Y. H. Li, Xintong Fortin, Stephen Minty, Evan Suchard, Marc A. |
author_facet | Schuemie, Martijn J. Arshad, Faaizah Pratt, Nicole Nyberg, Fredrik Alshammari, Thamir M Hripcsak, George Ryan, Patrick Prieto-Alhambra, Daniel Lai, Lana Y. H. Li, Xintong Fortin, Stephen Minty, Evan Suchard, Marc A. |
author_sort | Schuemie, Martijn J. |
collection | PubMed |
description | Background: Routinely collected healthcare data such as administrative claims and electronic health records (EHR) can complement clinical trials and spontaneous reports to detect previously unknown risks of vaccines, but uncertainty remains about the behavior of alternative epidemiologic designs to detect and declare a true risk early. Methods: Using three claims and one EHR database, we evaluate several variants of the case-control, comparative cohort, historical comparator, and self-controlled designs against historical vaccinations using real negative control outcomes (outcomes with no evidence to suggest that they could be caused by the vaccines) and simulated positive control outcomes. Results: Most methods show large type 1 error, often identifying false positive signals. The cohort method appears either positively or negatively biased, depending on the choice of comparator index date. Empirical calibration using effect-size estimates for negative control outcomes can bring type 1 error closer to nominal, often at the cost of increasing type 2 error. After calibration, the self-controlled case series (SCCS) design most rapidly detects small true effect sizes, while the historical comparator performs well for strong effects. Conclusion: When applying any method for vaccine safety surveillance we recommend considering the potential for systematic error, especially due to confounding, which for many designs appears to be substantial. Adjusting for age and sex alone is likely not sufficient to address differences between vaccinated and unvaccinated, and for the cohort method the choice of index date is important for the comparability of the groups. Analysis of negative control outcomes allows both quantification of the systematic error and, if desired, subsequent empirical calibration to restore type 1 error to its nominal value. In order to detect weaker signals, one may have to accept a higher type 1 error. |
format | Online Article Text |
id | pubmed-9299244 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92992442022-07-21 Vaccine Safety Surveillance Using Routinely Collected Healthcare Data—An Empirical Evaluation of Epidemiological Designs Schuemie, Martijn J. Arshad, Faaizah Pratt, Nicole Nyberg, Fredrik Alshammari, Thamir M Hripcsak, George Ryan, Patrick Prieto-Alhambra, Daniel Lai, Lana Y. H. Li, Xintong Fortin, Stephen Minty, Evan Suchard, Marc A. Front Pharmacol Pharmacology Background: Routinely collected healthcare data such as administrative claims and electronic health records (EHR) can complement clinical trials and spontaneous reports to detect previously unknown risks of vaccines, but uncertainty remains about the behavior of alternative epidemiologic designs to detect and declare a true risk early. Methods: Using three claims and one EHR database, we evaluate several variants of the case-control, comparative cohort, historical comparator, and self-controlled designs against historical vaccinations using real negative control outcomes (outcomes with no evidence to suggest that they could be caused by the vaccines) and simulated positive control outcomes. Results: Most methods show large type 1 error, often identifying false positive signals. The cohort method appears either positively or negatively biased, depending on the choice of comparator index date. Empirical calibration using effect-size estimates for negative control outcomes can bring type 1 error closer to nominal, often at the cost of increasing type 2 error. After calibration, the self-controlled case series (SCCS) design most rapidly detects small true effect sizes, while the historical comparator performs well for strong effects. Conclusion: When applying any method for vaccine safety surveillance we recommend considering the potential for systematic error, especially due to confounding, which for many designs appears to be substantial. Adjusting for age and sex alone is likely not sufficient to address differences between vaccinated and unvaccinated, and for the cohort method the choice of index date is important for the comparability of the groups. Analysis of negative control outcomes allows both quantification of the systematic error and, if desired, subsequent empirical calibration to restore type 1 error to its nominal value. In order to detect weaker signals, one may have to accept a higher type 1 error. Frontiers Media S.A. 2022-07-06 /pmc/articles/PMC9299244/ /pubmed/35873596 http://dx.doi.org/10.3389/fphar.2022.893484 Text en Copyright © 2022 Schuemie, Arshad, Pratt, Nyberg, Alshammari, Hripcsak, Ryan, Prieto-Alhambra, Lai, Li, Fortin, Minty and Suchard. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Schuemie, Martijn J. Arshad, Faaizah Pratt, Nicole Nyberg, Fredrik Alshammari, Thamir M Hripcsak, George Ryan, Patrick Prieto-Alhambra, Daniel Lai, Lana Y. H. Li, Xintong Fortin, Stephen Minty, Evan Suchard, Marc A. Vaccine Safety Surveillance Using Routinely Collected Healthcare Data—An Empirical Evaluation of Epidemiological Designs |
title | Vaccine Safety Surveillance Using Routinely Collected Healthcare Data—An Empirical Evaluation of Epidemiological Designs |
title_full | Vaccine Safety Surveillance Using Routinely Collected Healthcare Data—An Empirical Evaluation of Epidemiological Designs |
title_fullStr | Vaccine Safety Surveillance Using Routinely Collected Healthcare Data—An Empirical Evaluation of Epidemiological Designs |
title_full_unstemmed | Vaccine Safety Surveillance Using Routinely Collected Healthcare Data—An Empirical Evaluation of Epidemiological Designs |
title_short | Vaccine Safety Surveillance Using Routinely Collected Healthcare Data—An Empirical Evaluation of Epidemiological Designs |
title_sort | vaccine safety surveillance using routinely collected healthcare data—an empirical evaluation of epidemiological designs |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299244/ https://www.ncbi.nlm.nih.gov/pubmed/35873596 http://dx.doi.org/10.3389/fphar.2022.893484 |
work_keys_str_mv | AT schuemiemartijnj vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns AT arshadfaaizah vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns AT prattnicole vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns AT nybergfredrik vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns AT alshammarithamirm vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns AT hripcsakgeorge vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns AT ryanpatrick vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns AT prietoalhambradaniel vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns AT lailanayh vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns AT lixintong vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns AT fortinstephen vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns AT mintyevan vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns AT suchardmarca vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns |